Jump to:
Poolbeg Pharma PLC Fundamentals
| Company Name | Poolbeg Pharma PLC | Last Updated | 2025-06-27 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 697.200 m | Market Cap | £23.08 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.01 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
|---|
| Asset Equity Ratio | 1.1050 | Cash Equity Ratio | 0.8437 |
|---|
| Quick Ratio | 8.5657 | Current Ratio | 8.79 |
|---|
| Price To Book Value | 2.4062 | ROCE | 0 |
|---|
Poolbeg Pharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Poolbeg Pharma PLC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|
| Tangible Assets | 0 | 0 | 0 |
| Intangible Assets | £1.68 m | £1.93 m | £2.13 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £1.68 m | £1.93 m | £2.13 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £519,000.00 | £700,000.00 | £878,000.00 |
| Cash & Equivalents | £7.82 m | £12.17 m | £16.19 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £10.25 m | £15.43 m | £19.29 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|
| Creditors within 1 year | £974,000.00 | £986,000.00 | £966,000.00 |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £974,000.00 | £986,000.00 | £966,000.00 |
| Net assets | £9.27 m | £14.44 m | £18.32 m |
| Equity | 2024 | 2023 | 2022 |
|---|
| Called up share capital | £100,000.00 | £100,000.00 | £100,000.00 |
| Share Premium | £23.10 m | £23.10 m | £23.10 m |
| Profit / Loss | -£5.94 m | -£4.50 m | -£4.78 m |
| Other Equity | £9.27 m | £14.44 m | £18.32 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £9.27 m | £14.44 m | £18.32 m |
| Ratios | 2024 | 2023 | 2022 |
|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.1050 | 1.1050 | 1.1050 |
| Cash / Equity | 0.8437 | 0.8437 | 0.8437 |
| EPS | -£0.01 | -£0.01 | -£0.01 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|
| Cash from operating activities | -£4.65 m | -£4.38 m | -£4.37 m |
| Cashflow before financing | -£4.65 m | -£4.38 m | -£4.37 m |
| Increase in Cash | -£4.35 m | -£4.02 m | -£4.76 m |
| Income | 2024 | 2023 | 2022 |
|---|
| Turnover | 0 | 0 | 0 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -£6.37 m | -£5.04 m | -£4.99 m |
| Pre-Tax profit | -£5.94 m | -£4.50 m | -£4.78 m |
Poolbeg Pharma PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to development of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire. |
|---|
| Latest Interim Date | 18 Sep 2024 |
|---|
| Latest Fiscal Year End Date | 20 May 2025 |
|---|
Poolbeg Pharma PLC Directors
| Appointed | Name | Position |
|---|
| 2023-11-30 | Mr. Patrick Joseph Ashe | Non-Executive Director |
| 2025-06-25 | Mr. Cathal Martin Friel | Executive Director,Chairman |
| 2025-05-27 | Professor Brendan Buckley | Non-Executive Director |
| 2025-05-27 | Dr. Jeremy Skillington | Executive Director,Chief Executive Officer |
| 2025-05-27 | Mr. Ian O'Connell | Executive Director,Chief Financial Officer |
Poolbeg Pharma PLC Contact Details
Poolbeg Pharma PLC Advisors
